The Immune Monitoring Shared Resource (IMSR) provides (1) state-of-the-art immunoassays to allow NCCC clinicians to monitor the immune responses of patients enrolled in clinical trials;(2) quality control and quality assurance, including validation of the reproducibility of the result;(3) expert guidance in the choice and interpretation of immunoassays most relevant to a particular study or clinical trial;and (4) a resource for all NCCC Investigators and the Dartmouth community to use dedicated instruments not normally available in individual laboratories?e.g., ELISPOT reader, autoMACS, Robosep, Luminex. In 2005, the IMSR began a process of Proficiency Testing through membership in the Cancer Vaccine Consortium, and that has continued. Initial participation was in the ELISPOT panel, and, in 2007, participation was extended for the first time to pentamer-staining. The total operating budget for FY 2007 was $365,161, with total chargebacks of $109,773 requiring $255,388 in non-chargeback subvention, derived from a combination of the NCCC CCSG and Institutional resources. There is strong institutional support for this Shared Resource that comes from Dartmouth Medical School, from the NIH-NCRR COBRE Immunology/Inflammation Program Project, the Immunotherapy Center, the Department of Microbiology and Immunology, and the Department of Neurology. NCCC provided $66,603 or 26% of this non-chargeback subvention. We are requesting a budget of $117,498 from the NCCC CCSG for the first year of the competitive renewal, representing a more proportionate level than current support, approximately 45% of the non-chargeback subvention needed to support. The IMSR currently provides 18 NCCC members and their laboratories with services valued at $52,708 in chargebacks for FY 2007. NCCC members represent 72% of the total laboratories using this facility at Dartmouth. They used 61% of the services rendered, and that usage constitutes 48% of the total chargeback fees.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA023108-32
Application #
8015003
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-12-01
Budget End
2010-11-30
Support Year
32
Fiscal Year
2010
Total Cost
$172,642
Indirect Cost
Name
Dartmouth College
Department
Type
DUNS #
041027822
City
Hanover
State
NH
Country
United States
Zip Code
03755
Soneji, Samir S; Sung, Hai-Yen; Primack, Brian A et al. (2018) Quantifying population-level health benefits and harms of e-cigarette use in the United States. PLoS One 13:e0193328
Durand, Marie-Anne; Yen, Renata West; O'Malley, A James et al. (2018) What matters most: protocol for a randomized controlled trial of breast cancer surgery encounter decision aids across socioeconomic strata. BMC Public Health 18:241
Courtney, Andrea L; Rapuano, Kristina M; Sargent, James D et al. (2018) Brain Reward Responses Are Behaviorally Relevant: The Authors Respond. J Stud Alcohol Drugs 79:41-42
Tosteson, Anna N A; Yang, Qian; Nelson, Heidi D et al. (2018) Second opinion strategies in breast pathology: a decision analysis addressing over-treatment, under-treatment, and care costs. Breast Cancer Res Treat 167:195-203
Molodtsov, Aleksey; Turk, Mary Jo (2018) Tissue Resident CD8 Memory T Cell Responses in Cancer and Autoimmunity. Front Immunol 9:2810
Elder, David E; Piepkorn, Michael W; Barnhill, Raymond L et al. (2018) Pathologist characteristics associated with accuracy and reproducibility of melanocytic skin lesion interpretation. J Am Acad Dermatol 79:52-59.e5
Rutter, Carolyn M; Kim, Jane J; Meester, Reinier G S et al. (2018) Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. Cancer Epidemiol Biomarkers Prev 27:158-164
Lin, Anping; Yin, Juan; Cheng, Chao et al. (2018) Decreased expression of FOXA2 promotes eutopic endometrial cell proliferation and migration in patients with endometriosis. Reprod Biomed Online 36:181-187
Punshon, Tracy; Jackson, Brian P (2018) Essential micronutrient and toxic trace element concentrations in gluten containing and gluten-free foods. Food Chem 252:258-264
Pernas, Sonia; Martin, Miguel; Kaufman, Peter A et al. (2018) Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. Lancet Oncol 19:812-824

Showing the most recent 10 out of 1911 publications